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Background and purpose: It is well recognized that low-density lipoprotein cholesterol (LDL-C)-lowering
therapy is effective for primary and secondary prevention of cerebrovascular/cardiovascular disease.
Ezetimibe, an inhibitor of the Niemann-Pick C1-Like 1 cholesterol transporter, is a relatively new drug
for LDL-C-lowering therapy in addition to statins. However, comparison between an aggressive LDL-C-
lowering therapy with a combination of statin and ezetimibe versus a standard LDL-C-lowering therapy
with statin alone is still unclear in terms of their effects on stabilization and volume regression of coro-
nary plaque. The ZIPANGU (Ezetimibe clinical investigation for the regression of intracoronary plaque
evaluated by angioscopy and ultrasound) study is aimed at comparing these two types of therapy based
on indices of plaque characteristics using non-obstructive coronary angioscopy and intravascular ultra-
sound.
Methods: The study is a multi-center, prospective, randomized, open-label, blinded-endpoint trial.
Through a centralized enrollment method, patients will be allocated to either monotherapy with ator-
vastatin alone or to combination therapy with atorvastatin (maximum: 20mg/day) and ezetimibe
(10mg/day). The target LDL-C level will be <100mg/dL for the monotherapy group and <70mg/dL for
the combination therapy group. At the baseline and the follow-up period of 9 months, non-obstructive
coronary angioscopy and intravascular ultrasound will be performed to compare the changes in plaque
color and volume between the two groups.
Conclusions: The ZIPANGU study will clarify whether combination therapy with statins and ezetimibe is
better for stabilizing coronary plaque as secondary prevention than monotherapy by statins alone. The
study will give new insights into lipid-lowering guidelines in Japan.
© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.∗ Corresponding author at: Division of Cardiology, Department ofMedicine, Nihon
niversity School of Medicine, 30-1 Oyaguchi-Kamicho, Itabashi, Tokyo 173-8610,
apan. Tel.: +81 3 3972 8111x2412; fax: +81 3 3972 1098.
E-mail address: hiro.takafumi@nihon-u.ac.jp (T. Hiro).
ttp://dx.doi.org/10.1016/j.jjcc.2014.02.026
914-5087/© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reIntrodutionA number of large-scale studies have suggested that low-
density lipoprotein cholesterol (LDL-C)-lowering therapy is
effective for primary and secondary prevention of cerebrovas-
cular/cardiovascular disease [1]. Based on the results of such
served.
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pants. Fig. 1 presents a ﬂowchart of the study protocol. In this
study, we exclude patients with ACS, including unstable angina
pectoris and acute myocardial infarction in the past 3 months. The
diagnosis of ACS is made based on the fulﬁllment of at least two of
Table 1
Inclusion and exclusion criteria.
Inclusion criteria
Eligible subjects are those who are scheduled to undergo elective
percutaneous coronary intervention (PCI), have yellow plaques
(grades 2–4) as observed by angioscopy (regardless of the presence or
absence of treatment with statins), and fulﬁll the following criteria:
1) Treatment with statins regardless of LDL-C level, and non-treatment
with statins at an LDL-C level of <100mg/dL
2) Age, 20–80 years (in principle), either male or female
3) Provision of informed consent for participation in the study
Exclusion criteria
Ineligible subjects are those meeting any of the following criteria:
1) Past history of drug hypersensitivity
2) Triglycerides, ≥400mg/dL
3) Serious liver diseasea or kidney diseaseb as a complication
4) HbA1c (JDS, ≥8% or NGSP, ≥8.4%), or treatment with insulin
5) Development of acute coronary syndrome (acute myocardial
infarction and unstable angina pectoris) in the past three months
6) Secondary hyperlipidemia patients and drug-induced hyperlipidemia
patients
7) Malignant tumor (excluding past history of malignant tumor)
8) Familial hypercholesterolemia or pregnancy, lactation, or possible
pregnancy
9) Treatment with cyclosporine
10) Other judgment of ineligibility by the supervising physician
LDL-C, low-density lipoprotein-cholesterol; AST, aspartate aminotransferase; ALT,
alanine aminotransferase;HbA1c, glycosylatedhemoglobinA1c; JDS, JapanDiabetes02 T. Hiro et al. / Journal of
arge-scale interventional studies, the National Cholesterol Edu-
ation Program Adult Treatment Panel (NCEP ATP) III in the USA
ecommends [2] that LDL-C levels should be kept below 70mg/dL
or secondary prevention of cerebrovascular/cardiovascular dis-
ase. Both European Society of Cardiology/European Atheroscle-
osis Society [3] and Canadian Lipid Guidelines [4] also make
imilar statements regarding LDL-C levels. These recommendations
trongly support the concept that where LDL-C is concerned, “the
ower, the better” [5].
In Japan, the Japan Atherosclerosis Society guidelines for
econdary prevention of arteriosclerotic disease in 2012 recom-
ended that LDL-C should be kept below 100mg/dL [6]. Although
he question of a lower level has been discussed, no relevant
riginal outcome data for Japanese individuals have been estab-
ished. Moreover, actual attainment of even the recommended
evel is not satisfactory. According to the Japan Lipid Guide-
ine Achievement Program (JL-GAP), the attainment rate for the
arget LDL-C level of <100mg/dL for secondary prevention of cere-
rovascular/cardiovascular diseasewas approximately 25% [7], and
ccording to the NCEP ATP III, attainment of LDL-C <70mg/dL
as 18% [8]. These real-world data may stem from insufﬁcient
ecognition amongphysicians of the importance of LDL-C-lowering
herapy, or the inherently limited efﬁcacy of LDL-C-lowering drugs,
specially statins. However, it may also be possible that the LDL-C
bsorption mechanism of the intestine is enhanced during statin
herapy [9].
Ezetimibe has become available for clinical practice and has
een gaining attention as a useful drug for LDL-C-lowering therapy
ecause it inhibits the Niemann-Pick C1-Like 1 (NPC1L1) choles-
erol transporter and thereby regulates cholesterol absorption [10].
ombination therapy with ezetimibe and statins also reportedly
owered LDL-C levels by approximately 25% versus statins alone
11]. Combination therapy with atorvastatin 10mg daily and eze-
imibe 10mgdaily is alsomore effective than a double dose (20mg)
f atorvastatin [12,13] and is equivalent to 80mg of atorvastatin
14]. The SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) trial
onducted among 1900 aortic stenosis patients mainly in North
merica also investigated the preventive effects of combination
herapy with ezetimibe and statins on cardiovascular disease.
lthough there were no differences in preventive effect on major
ardiovascular diseases between a placebo group and the combina-
ion therapy group, combination therapywas signiﬁcantly superior
o placebo in terms of preventive effect on ischemic heart disease
15]. Kouvelos et al. reported as a pilot prospective randomized
tudy that the incidence of cardiovascular disease was reduced by
he combination of rosuvastatin and ezetimibe compared to the
onotherapy of rosuvastatin alone in patients undergoing vascu-
ar surgery [16]. The SHARP (Study of Heart and Renal Protection)
rial was performed including 9400 chronic kidney disease (CKD)
atients in theUSA and Europe to investigate the preventive effects
f ezetimibe and simvastatin combination therapy on cardiovascu-
ar disease. The results of this trial provided evidence for safe and
ffective lowering of LDL-C with a combination of ezetimibe and
imvastatin among a wide range of patients with CKD [17]. A ran-
omized interventional study of the simvastatin/ezetimibe ﬁxed
ombination drug VytorinTM (Merck, Whitehouse Station, NJ, USA)
s now ongoing among 18,000 patients with acute coronary syn-
rome (ACS). The IMPROVE-IT (improved reduction of outcomes;
ytorin efﬁcacy international trial) study seeks to investigate the
reventive effect of ezetimibe and simvastatin combination ther-
py on cardiovascular disease [18]. In Japan, however, the relatively
ow incidence of cardiovascular disease in Japanese versusWestern
ndividuals makes a large-scale outcome study difﬁcult to achieve.
Previous reports stated that vulnerable coronary plaques such
s thin-cap ﬁbroatheroma are closely related to provocation of ACS
r myocardial infarction. This ﬁnding suggests that stabilizationlogy 64 (2014) 501–507
of coronary plaques is important for prevention of cardiovascular
disease [19,20]. Vulnerableplaques canbedetected angioscopically
as yellow color [21]. Using non-obstructive coronary angioscopy,
we reported that LDL-C-lowering therapy can change the color of
plaques from yellow to white and can stabilize the vascular intima
[22,23]. Because combination therapy with ezetimibe and statins
exhibits amorepotent LDL-C-loweringeffect thana statinalone,we
might expect combination therapy to provide a better stabilizing
effect on coronary plaque than that from a statin alone. However, it
remains unclear whether the “lower is better” notion surrounding
LDL-C is applicable to plaque stabilization.
Aims and hypotheses
TheZIPANGU (Ezetimibe clinical investigation for the regression
of intracoronary plaque evaluated by angioscopy and ultrasound)
study is aimed at comparing aggressive LDL-C-lowering therapy
with statins and ezetimibe versus therapywith statins alone, based
on indices of coronary artery plaque color and volume.
Study design
The study is a multi-center, prospective, randomized, open-
label, blinded-endpoint (PROBE) trial. The protocol received Nihon
University human research ethics approval in September 2011, and
the ﬁrst patient was enrolled in November 2011. The study is reg-
istered in the UMIN Clinical Trial Registry (UMIN-CTR).
Study protocol
Table 1 presents inclusion and exclusion criteria for partici-Society; NGSP, National Glycohemoglobin Standardization Program.
a Either AST or ALT more than three times as high as the upper limit of the appli-
cable normal range.
b Dialysis patients, serum creatinine level, ≥2.0mg/dL or creatinine kinase,
≥500 IU/L.
T. Hiro et al. / Journal of Cardiology 64 (2014) 501–507 503
Fig. 1. Flowchart of the study protocol. Patients will be allocated to either monotherapy with atorvastatin alone or to combination therapy with atorvastatin and ezetimibe
(10mg/day). Treatment will begin within 72h of percutaneous coronary intervention (PCI). The target low-density lipoprotein cholesterol level will be <100mg/dL for
the monotherapy group and <70mg/dL for the combination therapy group, in which atorvastatin is administered from the start dosage of 10mg/day and then titrated by
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wncreasing the dosage up to a maximum of 20mg daily. At the baseline and 9±2 mo
lood examinations are taken at the baseline (0M), 1 month±2 weeks, 3 months±
he following three criteria: (1) evidence of coronary ischemia on
lectrocardiogram; (2) increase (≥2-fold) in the serum creatinine
inase (CK) or CK-MB levels and/or troponin-T positivity; and (3)
resence of symptoms suggestive of ACS.
After obtaining informedconsent, the supervisingphysicianwill
omplete a subject enrollment sheet and enter necessary data on
he website of the data center, Nouvelle Place Inc., Tokyo, Japan.
hrough a centralized enrollment method, patients will be allo-
ated to either monotherapy with atorvastatin alone (10mg/day)
r to combination therapy with atorvastatin (10mg/day) and
zetimibe (10mg/day). Treatment will begin within 72h of per-
utaneous coronary intervention (PCI). The target LDL-C level will
e <100mg/dL for the monotherapy group and <70mg/dL for
he combination therapy group. If LDL-C levels are higher than
00mg/dL within 3 months after the start of treatment in the
onotherapy group, or if LDL-C levels are higher than 70mg/dL
ithin 3 months in the combination group, atorvastatin dosage
ill be increased to a maximum of 20mg, regardless of group
ssignment.
Patients will be counseled on lifestyle improvement in accor-
ance with the 2012 Guidelines for Prevention of Atherosclerotic
ardiovascular Diseases issued by the Japan Atherosclerosis Soci-
ty [6]. The diet therapy and the medical therapy for other
omplications or for prevention of atherosclerosis except lipid
anagement are administered comprehensively for each of
he enrolled patients by individual strategy of the attending
hysicians.
The study period is deﬁned as the period of enrollment and
ollow-up observation (9±2 months). During follow-up, medica-
ion compliance for investigational drugswill be checked regularly.
n principle, treatment methods for hyperlipidemia will not be
hanged.
andomized allocation and allocation factors
Patientswill be allocated randomly via the Internet to either the
onotherapy group or the combination therapy group at a ratio of
:1, in accordance with the following allocation factors: (1) LDL-
level at study enrollment, (2) any diabetic status [hemoglobin
1c (Japan Diabetes Society: ≥6.1% and National Glycohemoglobin
tandardization Program: ≥6.5%)], and (3) any previous treatment
ith statins.llow-up period, coronary angioscopy and intravascular ultrasound are performed.
ks, and 9±2 months. IVUS, intravascular ultrasound.
Observational indices
Observation indices at enrollment and9±2months after enroll-
ment are as follows (Table 2).
1) Non-obstructive angioscopy
Aﬁber catheter andnon-obstructive ﬁber imaging system (FT-
201, InterTec Co. Ltd., Osaka, Japan) will be used. The color of
plaques will be investigated ﬁrst by visual inspection (primary
data) and then supported by a digital analytical device (sec-
ondary data). Color will be classiﬁed into ﬁve grades according
to yellow grade [22]. As many as possible plaque segments will
be selected to be analyzed by both angioscopy and intravascu-
lar ultrasound (IVUS), whether the location is proximal or distal
to the PCI site, or whether within culprit vessel or non-culprit.
This is not only because the total case number is limited, but also
becausewhether our datawill be affected by plaque localization
is currently unknown, which may be clariﬁed by a sub-analysis.
2) IVUS
IVUS will be performed with a 40MHz catheter (Atlantis SR
Pro2) using an iLab IVUS System (Boston Scientiﬁc Inc., Natick,
MA, USA). This system will be used to measure plaque volume,
lumens, and vessels of at least 5.0mm longitudinal length. Tis-
sue characteristics of plaques will be investigated using iMAP
(Boston Scientiﬁc). The reliability and limitations of iMAP were
previously described in several reports [24,25].
At the central core laboratory, two independent experienced
investigators who are unaware of the patient group allocation
as well as the imaging date (baseline or follow-up) perform the
quantitative IVUS analysis. The two IVUS images (blinded to
whether baseline or follow-up) are reviewed together on a dis-
play, and target segmentswith a yellowgrade equal to or greater
than grade 1 are selected, referring to angioscopic examination.
The target segment is determined at a non-PCI site (>5mmprox-
imal or distal to the PCI site) of culprit vessel or at a site of
non-culprit vessel with a reproducible index, usually a branch
site. Spotty calciﬁcation, side vein, and distances from side
branch, oriﬁce, left anterior descending–left circumﬂex branch
bifurcation, and stent edgealsoare referred. Subsequently, every
6th image (0.1mm apart) is manually traced on a commercially
available IVUS measurement software (echoPlaque 4, INDEC
systems Inc., Santa Clara, CA, USA). Moreover, this software
504 T. Hiro et al. / Journal of Cardiology 64 (2014) 501–507
Table 2
Test schedule.
Follow-up period
At enrollment 1 month 3 months 9±2 months Discontinuing
Patient characteristics X
Medication compliance X X X X
Adverse events
Observational indices
Blood pressure X X X X X
Pulse rate X X X X X
Height X
Weight X X X X X
Angioscopy X X
IVUS X X
Serum lipid
TC X X X X X
LDL-C X X X X X
TG X X X X X
HDL-C X X X X X
RLP-C X X X X X
Glucose metabolism
Fasting blood glucose X X X
HbA1C X X X
Insulin (IRI) X X X
Adipocytokine
High-molecular-weight adiponectin X X X
Inﬂammation marker
High-sensitivity CRP X X X
Cholesterol synthesis/absorption markers
Lanosterol X X X
Sitosterol X X X
Campesterol X X X
Others
AST, ALT, -GTP, ChE, CPK, serum creatinine, BUN, eGFR X X X X X
IVUS, intravascular ultrasound; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; RLP-C, rem-
nant like particles cholesterol; HbA1c, glycosylated hemoglobin A1c; IRI, immunoreactive insulin; CRP, C-reactive protein; AST, aspartate aminotransferase; ALT, alanine
a PK, cr
ﬁ
“ eriod.
3minotransferase; -GTP, gamma-glutamyl transpeptidase; ChE, cholinesterase; C
ltration rate.
X” means that the parameters or markers will be examined at the corresponded p
automatically interpolated the tracing of ﬁve cross sections in
between the two manually traced images.
Then, lumen area, external-elastic membrane (EEM) area, and
plaque area (EEMareaminus lumenarea) aremeasured. Accord-
ing to these consecutive area measurements, lumen, EEM, and
plaque volumes are calculated by the integration of these data.
The change in plaque volume is examined by % change in plaque
volume and net change of % volume of plaque compared to EEM
volume, over the follow-up period. The change in tissue char-
acteristics of plaque is examined similarly compared to total
plaque volume.
It is technically difﬁcult to completely match the position of
the examined plaque between IVUS and coronary angioscopy.
IVUS views cross-sectional structure of vessel, while coronary
angioscopy provides forward view of the surface of plaque.
Therefore, we have to meticulously determine its position
compared with American Heart Association coronary segment
classiﬁcation using simultaneous ﬂuoroscopy, especially by
referring to main branches, so that the examined coronary seg-
ment by IVUS longer than 5.0mm should include the target
yellow plaque as much as possible.
) Laboratory data
Lipid proﬁle and conventional clinical laboratory examina-
tions will be completed at enrollment and 1 month, 3 months,
and 9±2 months after enrollment. Special examinations for
glucose metabolism, inﬂammation, and cholesterol synthe-
sis/absorption markers will be completed at enrollment and
9±2 months after enrollment. Biomarkers will be measured
at a centralized laboratory by SRL, Inc. (Hachioji Laboratories,
Tokyo, Japan). The detailed schedule of the laboratory dataeatine phosphorus kinase; BUN, blood urea nitrogen; eGFR, estimated glomerular
examination is shown in Table 2. All the data are obtained
at the overnight fasting state. As for the markers of general
lipid metabolism, total cholesterol, LDL-cholesterol, high-
density lipoprotein cholesterol, triglyceride, and remnant-like
lipoprotein particle (RLP)-cholesterol are examined. The level
of LDL-cholesterol is calculated from the Friedewald formula.
As for the glucose metabolism, the fasting level of insulin
and glucose, and the level of hemoglobin A1c, are measured.
Regarding the cholesterol metabolism, the level of lathosterol
represented for the synthesis, and the level of sitosterol and
campesterol for absorption, are all examined.
Endpoints and evaluation
Primary endpoint:
Change in the color grade of coronary plaques, as assessed by
non-obstructive coronary angioscopy.
Secondary endpoints:
1) Changes in plaque volume corresponding to enrolled yellow
plaque as assessed by IVUS.
2) Change in tissue characteristics of plaque by IVUS (iMAP).
3) Change in blood markers for lipid metabolism, glucose
metabolism, adiponectin, high-sensitivity C-reactive protein,
and cholesterol synthesis/absorption.
4) Prevalence of cardiovascular events: non-fatal myocardial
infarction, non-fatal stroke, hospitalization due to unstable
angina pectoris, coronary revascularization (PCI/coronary artery
bypass graft), and cardiac death.
5) Incidence of adverse events.
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linding and key opening
Patients, doctors, supervising nurses, and other medical
roviders concernedwill perform the study on a non-blinded basis.
ata sets for primary and secondary endpoints will be assessed on
blinded basis by an Endpoint Assessment Committee as well as
he core laboratories for the examination of coronary angioscopic
nd IVUS images. This study is a PROBE study. The Endpoint Assess-
ent Committee will assess data sets on a blinded basis as needed
efore an interim analysis and a ﬁnal analysis. Key opening will be
arried out after data for all subjects are ﬁnalized.
ample size
There have been no reports from even a single center regarding
egree of improvement in yellow grade of plaque (YGP) in combi-
ation therapy with atorvastatin and ezetimibe. Our study is thus
xploratory research. However, some previous studies examining
he relationship between LDL-C levels and yellow grade of plaques
re useful for reference.
According to the previous reports [26,27], we hypothesize in
his study that LDL-C levels should be decreased by approximately
0mg/dL in the combination therapy group versus the monother-
pygroup (1.75-foldhigher lowering rate),whenLDL-C levels at the
tart of treatment are 140mg/dL. In order to determine the sam-
le size of this study, we also referred to two previous studies on
hange in YGP by statin. In the TWINS study [22], changes in the
ellow grade of plaques were compared before and after treatment
ithatorvastatin.WhenLDL-C levelsdecreased to<100mg/dLafter
reatment, mean YGP decreased from 1.5±0.8 to 1.1±0.5 (LDL-
144→86mg/dL). In the TOGETHAR study [23], darker colors of
laqueswere subject to investigation.WhenLDL-C levelsdecreased
o <100mg/dL after treatment, mean YGP decreased from 2.9±0.8
o 2.6±0.7 (LDL-C 145→94mg/dL). If mean YGP before the start
f the study is 2.5, mean YGP after treatment can be expected to
ecrease to 2.1 in the monotherapy group and 1.8 in the combina-
ion therapy group, if the degree of absolute decrease in LDL-C level
s signiﬁcantly correlated with YGP. Assuming a standard devia-
ionof 0.5, an intergroupdifference of 0.30±0.50 (mean± standard
eviation), power of 80%, and a 5% signiﬁcance level, 45 subjects
ill be necessary for each group. Assuming a dropout rate of 30%
including subjects excluded from analysis), the necessary number
f subjects is estimated at 65 per arm, and 130 in total.
nalysis of primary endpoints and statistics
Angioscopic images and IVUS images will be analyzed by a
ore laboratory which is independent of the medical institutions
onducting the study and has two or more specialists for image
nterpretation. Serial numbers will be assigned to plaque images
ecorded on DVDs for investigation at the entry and follow-up
eriods, and the associated patient name, assigned group, and
ecording date will be blinded to the core laboratories for image
nalysis.
We use full analysis set (FAS) of data for primary analyses. The
AS population is a trial population which is as close as possible to
he general population forwhich the related treatment is intended.
he FAS can include individuals who fail to comply with the treat-
ent protocol. In this study, data of patients are included in FAS
f patients with elective PCI have measurable coronary angioscopy
oth at the enrollment and at follow-up. We also prepared per-
rotocol set (PPS) analysis setofdata if enrolledpatients completely
et the inclusion and exclusion criteria and followed the protocol
s it was. The PPS population is the subset of the FAS popula-
ion which adheres to the treatment protocol. Consequently, thislogy 64 (2014) 501–507 505
population cannot include individuals who fail to comply with the
treatment protocol. When even the FAS cannot include a patient,
due to intention or proposal of discontinuation, ethical reasons,
too poor compliance, critical adverse outcomes, and severe com-
plications, the subject is withdrawn. In this analysis, cases taking
medication 3 days a week or more will be considered as compliant.
Inter-group differences will be assessed by multiple regression
analysis controlling for cardiovascular risk factors. However, the
effect of these potential confounders is likely to be minimized
through the randomization procedure. A two-sided test will be
used,with the level of signiﬁcancedesignated as <0.05. A sub-group
analysis based on background factors (e.g. sex, age, and diabetic
history, any prior history of treatmentwith statins)will also be per-
formed. Additional analytical items will be discussed as necessary.
Discussion
According to guidelines for the prevention of atherosclero-
sis in Japan, the target LDL-C level for secondary prevention of
atherosclerosis is <100mg/dL. However, there is no original scien-
tiﬁc evidence for this target LDL-C level from Japanese patients,
which suggests this level should be lower. At the same time,
results from research into treatment of lipid abnormalities by Ter-
amoto et al. in 2012 (JL-GAP) [7] state that the attainment rate of
this target LDL-C level in patients treated with statins was less
than 25%. However, in order to establish evidence in Japanese
individuals for the favorable signiﬁcance ofmore aggressive LDL-C-
lowering therapy than that recommended in Japanese guidelines, a
randomized interventional study is needed to suggest that aggres-
sive LDL-C-lowering therapy can signiﬁcantly prevent a recurrence
of arteriosclerotic events compared to standard LDL-C therapy.
Against this background, the ZIPANGU study is planned as an inter-
ventional study hypothesizing that the characteristics and volume
of plaques will be affected differentially in LDL-C-lowering treat-
ment by combination therapy with atorvastatin and ezetimibe
[target LDL-C level: <70mg/dL (aggressive LDL-C-lowering ther-
apy)] versus monotherapy with atorvastatin [target LDL-C level:
<100mg/dL (standard LDL-C lowering therapy)].
One of the main issues in this study might be whether the color
of coronary plaques and the volume of plaques can be used as
surrogate markers for clinical outcome. Previously, various multi-
center clinical studies have used carotid intima–media thickness
(IMT) as a surrogate marker. In the ENHANCE study [28], LDL-
C levels and high-sensitivity C-reactive protein were signiﬁcantly
improved in patients treated with ezetimibe and statins compared
to those treated with statins alone. The ENHANCE study showed
that IMT progression was comparable between the two groups.
However, this result should be considered with several limitations.
First, this study was only for patients with familial hypercho-
lesterolemia (LDL-C at baseline was approximately 320mg/dL).
Second, the average age of enrolled patients was approximately
46 years, in which half of them were female. Third, the IMT at
baseline was normal with a thickness of about 0.70mm. A large-
scale meta-analysis (PROG-IMT) [29] suggested recently that IMT
progression and cardiovascular events are not signiﬁcantly related
to each other. Therefore, in the present study, we decided to
directly examine whether the combination therapy can improve
coronaryatherosclerosis inpatientswith stable coronaryarterydis-
ease enrolled from a more general clinical situation. Consequently,
more objective surrogate markers for coronary atherosclerosis are
needed.IVUS has been used widely in multicenter studies to prove
the efﬁcacy of statins in secondary prevention by examining
whether there are any regressive or less progressive effects of
statins on plaque volume [30–36]. Nicholls et al. observed a
5 Cardio
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irect relationship between the IVUS-derived burden of coronary
therosclerosis, its progression, and adverse cardiovascular events
37]. The extended ESTABLISH study also revealed that plaque pro-
ressionor regressionwasa relatedclinical outcome[38].However,
he extended JAPAN-ACS study could not prove that change in
laque volume was a signiﬁcant surrogate marker for outcome and
howed, rather, that negative remodeling during statin treatment
epresented a clinical outcome [39], although the cardiovascular
vent rate was unexpectedly too low to conclude the surrogate
igniﬁcance of the marker. Accordingly, tissue characteristics of
laque rather than its burden may be more useful as a surrogate
arker. In fact, various studies using color IVUS for tissue charac-
erization have been performed to examine the effect of statins on
laque tissue composition [40–42]. The PROSPECT study showed
hat plaque burden, as well as some speciﬁc tissue characteristics
ermed thin-cap ﬁbro-atheroma, reﬂects clinical outcomes [43].
n this context, the study used a color IVUS system to examine
oth change in plaque volume and plaque tissue characteristics,
lthough it is not yet established that tissue characteristics and
hanges in coronary plaque can be considered more reliable sur-
ogate markers for clinical outcome than change in plaque volume.
Our study instead adopts a primary endpoint of plaque color
rade assessed by non-obstructive coronary angioscopy. Previous
tudies have shown on a semi-quantitative basis that change in the
ellow grade of plaque sensitively represented the effect of statins
n plaque stabilization [22,23]. The TWINS study showed that a
olor change of plaque came ﬁrst, followed by a plaque volume
hange during the statin study [22]. The presence of yellow grades
lso has a documented relation to worse clinical outcomes [21],
nd previous studies have revealed that vulnerable plaques can be
etected as yellow color by angioscopy [44]. We therefore selected
ellow grade of plaque as a primary endpoint in our study. This
ecisionalso camepartly fromtheadvantage resulting fromthe fact
hat study design and estimation of the data requirements could be
erformed more reasonably than with IVUS markers.
We believe that the present study may be the ﬁrst random-
zed, multi-center, interventional study to compare combination
herapy with ezetimibe and statins to monotherapy with statins.
Another impact of the study may be an opportunity to examine,
n part, the pleiotropic or inherent effect of ezetimibe. In a study
egarding secondary prevention with statins (Scandinavian Sim-
astatin Survival Study), a sub-analysis suggested that statins are
ffective in preventing the onset of cerebrovascular/cardiovascular
vents in thosewith lower cholesterol absorption, andarenoteffec-
ive in thosewith higher cholesterol absorption [45]. In theDEBATE
Drugs and Evidence-Based Medicine in the Elderly) study, the risk
f all-cause death and cerebrovascular/cardiovascular events was
igher in those with higher cholesterol absorption than in those
ith lower cholesterol absorption, even though the levels of LDL-
in both groups were equivalent [46]. It is thus possible that
zetimibe, unlike statins, may manifest other effects on plaque
haracteristics by inhibiting cholesterol absorption.
In conclusion, the ZIPANGU study will clarify whether combi-
ation therapy with statins and ezetimibe is better for stabilizing
oronary plaque as secondary prevention than monotherapy by
tatins alone. The study will give new insights into lipid-lowering
uidelines in Japan. Even if the results arenegativewithusing sensi-
ive plaque indices of IVUS as well as angioscopy, our study would
lso be clinically signiﬁcant, because it will give new discussion
egarding what the target value of LDL-C-lowering therapy should
e, or what the real effect of statins is.isclosures
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